The liposomal doxorubicin market is projected to grow from $1.32 billion in 2025 to $1.77 billion by 2030, while the broader breast cancer drugs market is expected to reach $54.49 billion by 2036. Growth is driven by increasing cancer incidence, adoption of targeted therapies, and advancements in drug delivery systems including liposomal formulations and antibody-drug conjugates.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07038369 |
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06970275 |
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery. |
RECRUITING | |
| NCT06960291 |
Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada |
RECRUITING | NA |
| NCT06929884 |
Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study |
ACTIVE_NOT_RECRUITING | |
| NCT06926075 |
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours |
RECRUITING | PHASE1/PHASE2 |
| NCT06915909 |
Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial |
NOT_YET_RECRUITING | NA |
| NCT06776172 |
Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0. |
RECRUITING | NA |
| NCT06717295 |
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling |
RECRUITING | |
| NCT06683846 |
Ivonescimab in the Treatment of Multiple Advanced Tumors |
RECRUITING | PHASE2 |
| NCT06675357 |
Using FAPI PET/MRI to Evaluate Prostate Cancer |
RECRUITING | PHASE2 |
